News >

Pembrolizumab Plus Epacadostat Active in RCC

Danielle Bucco
Published: Wednesday, Aug 02, 2017

Dr. Primo Lara

Primo N. Lara Jr, MD
The combination of the PD-1 inhibitor pembrolizumab (Keytruda) and the IDO-inhibitor epacadostat induced a response rate of 47% in patients with advanced renal cell carcinoma (RCC), according to results from the phase I/II KEYNOTE-037 study presented at the 2017 ASCO Annual Meeting.

during ASCO, Primo N. Lara Jr, MD, an associate director for Translational Research and co-leader of the Cancer Therapeutics Program at the UC Davis Comprehensive Cancer Center, discussed the KEYNOTE-037 pembrolizumab/epacadostat findings in patients with advanced RCC, and how the combination could change treatment in this population.

OncLive: Can you give an overview of the study investigating epacadostat and pembrolizumab?

Lara: The epacadostat/pembrolizumab trial was a phase Ib/II trial testing the IDO inhibitor epacadostat in combination with the PD-1 inhibitor pembrolizumab in a variety of solid tumors. The subset that we presented at ASCO this year was in metastatic renal cell carcinoma.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Publication Bottom Border
Border Publication